Stay updated with breaking news from Eric Widera. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MONDAY, July 17, 2023 (HealthDay News) -- Another experimental drug meant to slow the damage of Alzheimer’s appears poised to join a growing arsenal of new treatments for this memory-robbing
Another experimental drug meant to slow the damage of Alzheimer's appears poised to join a growing arsenal of new treatments for this memory-robbing disease.
Eli Lilly & Co. said it applied for full U.S. approval of its Alzheimer’s disease drug that’s expected to compete with Eisai Co.’s Leqembi as the U.S. drugmaker revealed details
Safety issues linger, as details of three deaths emerge
Patients given monthly infusions of Eli Lilly and Co.’s donanemab declined about four to seven months more slowly than those given dummy infusions in a large study